Dietary toxins, endoplasmic reticulum (ER) stress and diabetes

Current Diabetes Reviews

Volumn 4, Issue 2, 2008, Pages 146-156

  Hettiarachchi, Kalindi D ^a   Zimmet, Paul Z ^a,b   Myers, Mark A ^a  

^a MONASH UNIVERSITY   (Australia)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

Bafilomycin; Cytokines; Diabetes; Endoplasmic reticulum stress; Islet beta cell; Plecomacrolide

Indexed keywords

BAFILOMYCIN; CONCANAMYCIN A; CYTOKINE; GAMMA INTERFERON; GELDANAMYCIN; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; INSULIN; INTERLEUKIN 1BETA; MACROLIDE; MITOGEN ACTIVATED PROTEIN KINASE; NIGERICIN; NITRIC OXIDE; PROINSULIN; PROTEIN BCL 2; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATASE; THAPSIGARGIN; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA; TUNICAMYCIN;

AUTOIMMUNITY; CARROT; CELL DEATH; CELL STRESS; DIABETOGENESIS; DIETARY INTAKE; DISEASE COURSE; DRUG TARGETING; ENDOPLASMIC RETICULUM; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; FOOD CONTAMINATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GLUCOSE INTOLERANCE; HUMAN; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; MEDICAL RESEARCH; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PLANT DISEASE; PLANT ROOT; POTATO; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REVIEW; STREPTOMYCES; SUGAR BEET; VEGETABLE; VIRUS INFECTION;

DIABETES MELLITUS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; ENDOPLASMIC RETICULUM; HUMANS; INFANT, NEWBORN; INSULIN-SECRETING CELLS; ISLETS OF LANGERHANS; MODELS, BIOLOGICAL; PLANT EXTRACTS; STRESS, PHYSIOLOGICAL; TOXINS, BIOLOGICAL; VEGETABLES;

EID: 48749118120     PISSN: 15733998     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339908784220697     Document Type: Review

References (132)

1. Atkinson MA, Leiter EH. The NOD mouse model of type 1 diabetes: as good as it gets? Nat Med 1999; 5: 601-604.
2. Trudeau JD, Dutz JP, Arany E, Hill DJ, Fieldus WE, Finegood DT. Neonatal beta-cell apoptosis: a trigger for autoimmune diabetes? Diabetes 2000; 49: 1-7.
3. Homo-Delarche F, Drexhage HA. Immune cells, pancreas development, regeneration and type 1 diabetes. Trends Immunol 2004; 25: 222-9.
4. Roder ME, Knip M, Hartling SG, Karjalainen J, Akerblom HK, Binder C. Disproportionately elevated proinsulin levels precede the onset of insulin-dependent diabetes mellitus in siblings with low first phase insulin responses. The Childhood Diabetes in Finland Study Group. J Clin Endocrinol Metab 1994; 79: 1570-1575.
5. Hermann R, Knip M, Veijola R, et al. Temporal changes in the frequencies of HLA genotypes in patients with Type 1 diabetes- indication of a increased environmental pressure? Diabetologia 2003; 46: 420-425.
6. Tuomilehto J, Podar T, Brigis G, et al. Comparison of the incidence of insulin-dependent diabetes mellitus, in childhood among five Baltic populations during 1983-1988. Int J Epidemiol 1992; 21: 518-27.
7. Tuomilehto J, Virtala E, Karvonen M, et al. Increase in incidence of insulin-dependent diabetes mellitus among children in Finland. Int J Epidemiol 1995; 24: 984-992.
8. Gale EA. Rise of childhood type 1 diabetes in the 20th century. Diabetes 2002; 51: 3353-3361.
9. Bekris LM, Kavanagh TJ, Lernmark A. Targeting type 1 diabetes before and at the clinical onset of disease. Endocr Metab Immune Disord Drug Targets 2006; 6: 103-24.
10. Bodansky HJ, Staines A, Stephenson C, Haigh D, Cartwright R. Evidence for an environmental effect in the aetiology of insulin dependent diabetes in a transmigratory population. Br Med J 1992; 304: 1020-22.
11. Raymond NT, Jones JR, Swift PG, et al. Comparative incidence of Type 1 diabetes in children aged under 15 years from South Asian and White or Other ethnic backgrounds in Leicestershire, UK, 1989 to 1998. Diabetologia 2001; 44: B32-6.
12. Hypponen E, Laara E, Reunanen A, Jarvelin MR, Virtanen SM. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort, study. Lancet 2001; 358: 1500-3.
13. Stene LC, Ulriksen J, Magnus P, Joner G. Use of cod liver oil during pregnancy associated with lower risk of Type 1 diabetes in the offspring. Diabetologia 2000; 43: 1093-8.
14. Zella JB, McCary LC, DeLuca HF. Oral administration of 1,25-dihydroxyvitamin D3 completely protects NOD mice from insulin-dependent diabetes mellitus. Arch Biochem Biophys 2003; 417: 77-80.
15. Zella JB, DeLuca HF. Vitamin D and autoimmune diabetes. J Cell Biochem 2003; 88: 216-222.
16. Fronczak CM, Baron AE, Chase HP, et al. In utero dietary exposures and risk of islet autoimmunity in children. Diabetes Care 2003; 26: 3237-42.
17. Hettiarachchi KD, Zimmet PZ, Myers MA. Transplacental exposure to bafiloimycin disrupts pancreatic islet organogenesis and accelerates diabetes onset in NOD mice. J Autoimmun 2004; 22: 287-296.
18. Myers MA, Hettiarachchi K, Ludeman J, Wilson AJ, Wilson CR, Zimmet PZ. Dietary microbial toxins and Type 1 diabetes. Ann NY Acad Sci 2003; 1005: 418-22.
19. Myers MA, Mackay IR, Rowley MJ, Zimmet PZ. Dietary microbial toxins and type 1 diabetes-a new meaning for seed and soil. Diabetologia 2001; 44: 1199-200.
20. Araki E, Oyadomari S, Mori M. Impact of endoplasmic reticulum stress pathway on pancreatic beta-cells and diabetes mellitus. Exp Biol Med 2003; 228: 1213-1217.
21. Araki E, Oyadomari S, Mori M. Endoplasmic reticulum stress and diabetes mellitus. Intern Med 2003; 42: 7-14.
22. Zhang K, Kaufman RJ. The unfolded protein response: a stress signaling pathway critical for health and disease. Neurology 2006; 66: S102-9.
23. He B. Viruses, ER stress, and interferon responses. Cell Death Differ 2006; 13: 393-403.
24. Hong J, Yamaki K, Ishihara K, Ahn JW, Zee O, Ohuchi K. Induction of apoptosis of RAW 264.7 cells by the cytostatic macrolide apicularen A. J Pharm Pharmacol 2003; 55: 1299-309.
25. Gotoh T, Oyadomari S, Mori K, Mori M. Nitric oxide-induced apoptosis in RAW 264.7 macrophages is mediated by ER stress pathway involving ATF6 and CHOP. J Biol Chem 2002; 277: 12343-50.
26. Yang GH, Li S, Pestka JJ. Down-regulation of the encloplasmic reticulum chaperone GRP78/BiP by vomitoxin (Deoxynivalenol). Toxicol Appl Pharmacol 2000; 162: 207-17.
27. Isler JA, Skalet AH, Alwine JC. Human cytomegalovirus infection activates and regulates the unfolded protein response. J Virol 2005; 79: 6890-9.
28. Tardif KD, Waris G, Siddiqui A. Hepatilis C virus, ER stress, and oxidative stress. Trends Microbiol 2005; 13: 159-63.
29. Benali-Furet NL, Chami M, Houel L, et al. Hepatitis C virus core triggers apoptosis in liver cells by inducing ER stress and ER calcium depletion. Oncogene 2005; 24: 4921-33.
30. Boyce M, Yuan J. Cellular response to endoplasmic reticulum stress: a matter of life or death. Cell Death Differ 2006; 13: 363-73.
31. Schroder M, Kaufman RJ. ER stress and the unfolded protein responce. Mutat Res 2005; 569: 29-63.
32. Oakes SA, Lin SS, Bassik MC. Control of ER-initiated apoptosis by Bel-2 proteins. Curr Mol Med 2006; 6: 99-109.
33. Contreras JL, Smyth CA, Bilbao G, et al. Coupling endoplasmic reticulunt stress to cell death program in isolated human pancreatic islets: effects of gene transfer of Bel-2. Transpl Int 2003; 16: 537-542.
34. Oyadomari S, Araki E, Mori M. ER stress-mediated apoptosis in beta cells. Apoptosis 2002; 7: 335-345.
35. Rutkowski DT, Kaufman RJ. A trip to the ER: coping with stress, Trends Cell Blol 2004; 14: 20-28.
36. Sheu X, Zhang K, Kaufman RJ. The unfolded protein response - a stress signaling pathway of the endoplasmic reticulum. J Chem Neuroanat 2004; 28: 79-92.
37. Oyadomari S, Koizumi A, Takeda K, et al. Targeted disruption of the Chop gene delays endoplasmic reticulum stress-mediated diabetes. J Clin Invest 2002; 109: 525-532.
38. Sonenberg N, Newgard CB. Protein synthesis. The perks of balancing glucose. Science 2001; 293: 818-819.
39. Harding H, Zhang Y, Bertolotti A, Zeng H, Ron D. Perk is essential for translational regulation and cell survival during the unfolded protein response. Mol Cell 2000; 5: 897-904.
40. Ozcan U, Cao Q, Yilmaz E, et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 2004; 306: 457-461.
41. Lipson KL, Fonseca SG, Ishigaki S, et al. Regulation of insulin biosynthesis in pancreatic beta cells by an ER-resident protein kinase IRE1. Cell Metab 2006; 4: 245-254.
42. Delopine M, Nicolino M, Barrett T, Grolamaully M, Lathrop GM, Julier C. EIF2AK3, encoding translation initiation factor 2-alpha kinase 3, is mutated in patients with Wolcott-Rallison syndrome. Nat Genet 2000; 25: 406-409.
43. Barrett TG, Bundey SE. Wolfram (DIDMOAD) syndrome. J Med Genet 1997; 34: 838-41.
44. Rando TA, Horton JC, Layzer RB. Wolfram syndrome: evidence of a diffuse neurodegenerative disease by magnetic resonance imaging. Neurology 1992; 42: 1220-4.
45. Karasik A, O'Hara C, Srikanta S, et al. Genetically programmed selective islet beta-cell loss in diabetic subjects with Wolfram's syndrome. Diabetes Care 1989; 12: 135-8.
46. Inoue H, Tanizawa Y, Wasson J, et al. A gene encoding a transmembrane protein is mutated in patients with diabetes mellitus and optic atrophy (Wolfram syndrome). Nat Genet 1998; 20: 143-8.
47. Strom TM, Hortnagel K, Hofmann S, et al. Diabetes insipidus, diabetes mellitus, optic atrophy and deafness (DIDMOAD) caused by mutations in a novel gene (wolframin) coding for a predicted transmembrane protein. Hum Mol Genet 1998; 7: 2021-8.
48. Fonseca SG, Fukuma M, Lipson KL, et al. WFS1 is a novel component of the unfolded protein response and maintains homeostasis of the endoplasmic reticulum in pancreatic beta-cells. J Biol Chem 2005; 280: 39609-15.
49. Ishihara H, Takeda S, Tamura A, et al. Disruption of the WIFS1 gene in mice causes progressive beta-cell loss and impaired stimulus-secretion coupling in insulin secretion. Hum Mol Genet 2004; 13: 1159-70.
50. Riggs A, Bernal-Mizrachi E, Ohsugi M, et al. Mice conditionally lacking the Wolfram gene in pancreatic islet beta cells exhibit diabetes as a result of enhanced endoplasmic reticulum stress and apoptosis. Diabetologia 2005; 48: 2313-21.
51. Hayden MR, Tyagi SC, Kerklo MM, Nicolls MR. Type 2 diabetes mellitus as a conformational disease. J Pancreas 2005; 6: 287-302.
52. Csorba TR, Lyon AW. Abnormal proinsulin congeners as autoantigens that initiate the pathogenesis of Type 1 diabetes. Med Hypotheses 2005; 64: 186-191.
53. Narendran P, Mannering SI, Harrison LC. Proinsulin-a pathogenic autoantigen in type 1 diabetes. Autoimmun Rev 2003; 2: 204-210.
54. Rudy G, Stone N, Harrison LC, et al. Similar peptides from two beta cell autoantigens, proinsulin and glutamic acid decarboxylase, stimulate T cells of individuals at risk for insulin-dependent diabetes. Mol Med 1995; 1: 625-633.
55. Chen W, Bergerot I, Elliott JF. Evidence that a peptide spanning B-C junction of proinsulin is an early autoantigen epitope in the pathogenesis of Type 1 diabetes. J Immunol 2001; 167: 4923-4935.
56. Daniel D, Wegmann DR. Protection of non obese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23). Proc Natl Acad Sci USA 1996; 93: 956-960.
57. Muir A. Insulin immunization of non-obese diabetic mice induces a protective insulitis characterized by diminished intraislet interferon-gamma transcription. J Clin Invest 1995; 95: 628-634.
58. Hutchings P, Cooke A. Protection from insulin dependent diabetes mellitus afforded by insulin antigens in incomplete Freund's adjuvant depends on route of administration. J Autoimmun 1998; 11: 127-130.
59. French MB, Allison J, Cram D, et al. Transgenic expression of mouse proinsulin II prevents diabetes in nonobese diabetic mice. Diabetes 1997; 46: 34-39.
60. Daniel D, Gill RG, Schlott N, Wegmann D. Epitope specificity, cytokine production profile and diabetogenic activity of insulin-specific T cell clones isolated from NOD mice. Eur J Immunol 1995; 25: 1056-62.
61. Wong FS. Identification of an MHC-class I restricted autoantigen in type 1 diabetes by screening an organ specific cDNA library. Nat Med 1999; 5: 1026-31.
62. Thebault-Baumont K, Dubois-Laforgue D, Krief P, et al. Acceleration of type 1 diabetes mellitus in proinsulin 2-deficient mice. J Clin Invest 2003; 111: 851-857.
63. Dubois-Lafforgue D, Mogenet L, Thebault K, Jami J, Krief P, Boitard C. Proinsulin 2 knockout NOD mice: a model for genetic variation of insulin gene expression in type 1 diabetes. Diabetes 2002; 51: 489-493.
64. Liu M, Li Y, Cavener D, Arvan P. Proinsulin disulfide maturation and misfolding in the ER. J Biol Chem 2005; 208: 13209-13212.
65. Ron D. Proteotoxicity in the endoplasmic reticulum: lessons from the Akita diabetic mouse. J Clin Invest 2002; 109: 443-445.
66. Kayo T, Koizumi A. Mapping of murine diabetogenic gene mody on chromosome 7 at D7Mit258 and its involvement in pancreatic islet and beta cell development during the perinatal period. J Clin Invest 1998; 101: 2112-2118.
67. Heaton DA, Millward BA, Gray IP, et al. Increased proinsulin levels as an early indicator of B-cell dysfunction in non-diabetic twins of type 1 (insulin-dependent) diabetic patients. Diabetologia 1988; 31: 182-184.
68. Villar-Rodriguez C, Conget I, Casamitjana R, Vidal J, Manzanares JM, Gomis R. High proinsulin levels in late pre-IDDM stage. Diabetes Res Clin Pract 1997; 37: 145-148.
69. Spinas GA, Snorgaard O, Hartling SG, Oberholzer M, Berger W. Elevated proinsulin levels related to islet cell antibodies in first-degree relatives of IDDM patients. Diabetes Care 1992; 15: 632-637.
70. Hartling SG, Lindgren F, Dahlqvist G, Persson B, Binder C. Elevated proinsulin in healthy siblings of IDDM patients independent of HLA identity. Diabetes 1989; 138: 1271-1274.
71. Lindgren FA, Hattling SG, Dahlquist GG, Binder C, Efendic S, Persson BE. Glucose-induced insulin response is reduced and proinsulin response increased in healthy siblings of type 1 diabetic patients. Diabet Med 1991; 8: 638-643.
72. Seaquist ER, Kahn SE, Clark PM, Hales CN, Porte DJ, Robertson RP. Hyperproinsulinemia is associated with increased beta cell demand after hernipancreatectomy in humans. J Clin Invest 1996; 97: 455-460.
73. Halban PA, Irminger JC. Mutant proinsulin that cannot be converted is secreted efficiently from primary rat beta-cells via the regulated pathway. Mol Biol Cell 2003; 14: 1195-1203.
74. Hostens K, Pavlovic D, Zambre Y, et al. Exposure of human islets to cytokines can result in disproportionately elevated proinsulin release. J Clin Invest 1999; 104: 67-72.
75. Jaeschke A, Rincon M, Doran B, et al. Disruption of the Jnk2 (Mapk9) gene reduces destructive insulitis and diabetes in a mouse model of type 1 diabetes. Proc Natl Acad Sci USA 2005; 102: 6931-5.
76. Hirosumi J, Tuncman G, Chang L, et al. A central role for JNK in obesity and insulin resistance. Nature 2002; 420: 333-6.
77. Jaeschke A, Czech MP, Davis RJ. An essential role of the JIP1 scaffold protein for JNK activation in adipose tissue. Genes Dev 2004; 18: 1976-80.
78. Tuncman G, Hirosumi J, Solinas G, Chang L, Karin M, Hotamisligil GS. Functional in vivo interactions between JNK 1 and JNK2 isoforms in obesity and insulin resistance. Proc Natl Acad Sci USA 2006; 103: 10741-6.
79. 2+, leading to induction of endoplasmic reticulum stress in pancreatic beta-cells. Diabetes 2005; 54: 452-461.
80. Cnop M, Welsh N, Jonas J, Jorns A, Lenzen S, Eizirik DL. Mechanisms of pancreatic beta cell death in Type 1 and Type 2 diabetes. Many differences, Few similarities. Diabetes 2005; 54: S97-S107.
81. Oyadomari S, Takeda K, Takiguchi M, et al. Nitric oxide-induced apoptosis in pancreatic beta cells is mediated by the endoplasmic reticulum stress pathway. Proc Natl Acad Sci USA 2002; 98: 10845-50.
82. Pirot P, Eizirik DL, Cardozo AK. Interferon-gamma potentiates endoplasmic reticulum stress-induced death by reducing pancreatic beta cell defence mechanisms. Diabetologia 2006; 49: 1229-36.
83. Gotoh T, Mori M. Nitric oxide and endoplasmic reticulum stress. Arterioscler Thromb Vasc Biol 2006; 26: 1439-1446.
84. Demain AL. Pharmaceutically active secondary metabolites of microorganisms. Appl Microbiol Biotechnol 1999; 52: 455-63.
85. Drose S, Altendorf K. Bafilomycins and concanamycins as inhibitors of V-ATPases and P-ATPases. J Exp Biol 1997; 200: 1-8.
86. Forgac M. Structure, mechanism and regulation of the clathrin-coated vesicle and yeast vacuolar H(+)-ATPases. J Fxp Biol 2000; 203: 71-80.
87. 0 subunit c. J Biol Chem 2002; 277: 40544-40548.
88. Bowman BJ, Bowman EJ. Mutations in subunit C of the vacuolar ATPase confer resistance to bafilomycin and identify a conserved antibiotic binding site. J Biol Chem 2002; 277: 3965-72.
89. Gluck S, Nelson R. The role of the V-ATPase in renal epithelial H+ transport. J Exp Biol 1992; 172: 205-18.
90. +-ATPase cause renal tubular acidosis with sensorineural deafness. Nat Genet 1999; 21: 84-90.
91. Vaananen HK, Hentunen T, Lakkakorpi P, Parvinen EK, Sundqvist K, Tuukkanen J. Mechanism of osteoclast mediated bone resorption. Ann Chir Gynaecol 1988; 77: 193-196.
92. Scimeca JC, Franchi A, Trojani. C, et al. The gene encoding the mouse homologue of the human osteoclast-specific 111-kDa V-ATPase subunit bears a deletion in Osteosclerotic (oc/oc) mutants. Bone 2000; 26: 207-213.
93. Li Y, Chen W, Liang Y, Li E, Stashenko P. Atp6I deficient mice exhibit severe Osteopetrosis due to loss of osteoclast-mediated extracellular acidification. Nat Genet 1999; 23: 447-451.
94. Gagliardi S, Nadler G, Consolandi E, et al. 5-(5,6-Dichloro-2- indolyl)-2-methoxy-2,4-pentadienamides: novel and selective inhibitors of the vacuolar H+-ATPase of osteoclasts with bone antiresorptive activity. J Med Chem 1998; 41: 1568-73.
95. Niikura K. Vacuolar ATPase as a drug discovery target. Drugs News Perspect 2006; 19: 139-143.
96. Forgac M. Structure, function and regulation of the vacuolar (H+)- ATPases. FEBS Lett 1998; 440: 258-263.
97. Balbis A, Baquiran G, Dumas V, Posner BI. Effect of inhibiting vacuolar acidification on insulin signaling in hepatocytes. J Biol Chem 2004; 279: 12777-85.
98. Keeling DJ, Herslof M, Mattsson JP, Ryberg B. Tissue-selective inhibition of vacuolar acid pumps. Acta Physiol Scand Suppl 1998; 643: 195-201.
99. Hettiarachchi KD, Zimmet PZ, Myers MA. The effects of repeated exposure to sub-toxic doses of plecomacrolide antibiotics on the endocrine pancreas. Food Chem Toxicol 2006; 44: 1966-1977.
100. Hettiarachchi KD, Zimmet PZ, Myers MA. The plecomacrolide vacuolar-ATPase inhibitor, Bafilomycin, alters insulin signaling in MIN6 β-cells. Cell Biol Toxicol 2006; 22: 169-181.
101. Hyoda K, Hosoi T, Horie N, Okuma Y, Ozawa K, Nomura Y. P13K-Akt inactivation induced CHOP expression in endoplasmic reticulum-stressed cells. Biochem Biophys Res Commun 2005; 340: 286-290.
102. Muchmore SW, Sattler M, Liang H, et al. X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. Nature 1996; 381: 335-41.
103. Minn AJ, Velez P, Schendel SL, et al. Bel-x(L) forms an ion channel in synthetic lipid membranes. Nature 1997; 385: 353-7.
104. 2+ homeostasis in the endoplasmic reticulum. Cell Death Differ 2006; 13: 1409-18.
105. Hong J, Nakano Y, Yokomakura A, et al. Nitric oxide production by v-ATPase inhibitors bafilomycin Al and concanamycin A and its role in apoptosis in RAW 264.7 cells. J Pharmacol Exp Ther 2006; 319: 672-81.
106. Huss M, Sasse F, Kunze B, et al. Archazolid and apicularen: novel specific V-ATPase inhibitors. BMC Biochem 2005; 6: 13.
107. Hong J, Yokomakura A, Nakano Y, et al. Induction of nitric oxide production by the cytostatic macrolide apicularen A and possible role of nitric oxide in apicularen A-induced apoptosis in RAW 264.7 cells. J Pharmacol Exp Ther 2005; 312: 968-77.
108. Hong J, Yokomakura A, Nakano Y, et al. Inhibition of v-ATPase by the cytostatic macrolide apicularen A and its role in apicularen A-induced apoptosis in RAW 264.7 cells. FEBS Lett 2006; 580: 2723-30.
109. Marcu MG, Doyle M, Bertolotti A, Ron D, Hendershot L, Neckers L. Heat shock protein 90 modulates the unfolded protein response by stabilizing IRE1alpha. Mol Cell Biol 2002;22: 8506-13.
110. Miyata Y. Hsp90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents. Curr Pharm Des 2005; 11: 1131-8.
111. Mimnaugh EG, Xu W, Vos M, Yuan X, Neckers L. Endoplasmic reticulum vacuolization and valosin-containing protein relocalization result from simultaneous hsp90. inhibition by geldanamycin and proteasome inhibition by velcade. Mol Cancer Res 2006; 4: 667-81.
112. Lawson B, Brewer JW, Hendershot, LM. Geldanamycin, an hsp90/ GRP94-binding drug, induces increased transcriptign of ER chaperones via the ER stress pathway. J Cell Physiol 1998; 174: 170-8.
113. King RR, Lawrence CH, Clark MC. Correlation of pbytotoxin production with pathogenicity of streptomyces-scabies isolates from scab infected potato tubers. Am Potato J 1991; 68: 675-680.
114. Loria R, Bukhalid RA, Fry BA, King RR. Plant pathogenicity in the Genus Streptomyces. Plant Dis 1997; 81: 836-846.
115. Archuleta JG, Easton GD. The cause of deep pitted scab of potatoes. Am Potato J 1981; 58: 385-392.
116. Doering-Saad C, Kampfer P, Manulis S, et al. Diversity among Streptomyces strains causing potato scab. Appl Environ Microbiol 1992; 58: 3932-40.
117. Natsume M, Ryu R, Abe H. Production of phytotoxins, concanamycins A and B by Streptomyces spp. causing potato scab. Ann Phytopathol Soc Jpn 1996; 62: 411-413.
118. Natsume M, Yamada A, Tashiro N, Abe H. Differential production of phytotoxins and concanamycins A and B by potato common scab-causing Streptomyces. Ann Phytol Soc Jpn 1998; 64: 202-204.
119. Onkamo P, Vaananen S, Karvonen M, Tuomilehto J. Worldwide increase in incidence. of Type 1 diabetes-the analysis of the data on published incidence trends. Diabetologia 1999; 42: 1395-1403.
120. Myers M, Zimmet P, Mackay I. Toxic Type 1 diabetes. Rev Endo Met Disord 2003; 4: 225-231.
121. Gale EA. Spring harvest? Reflections on the rise of type 1 diabetes. Diabetologia 2005; 48: 2445-50.
122. Patterson CC, Dahlquist G, Soltesz G, Green A. Is childhood-onset type 1 diabetes a wealth-related disease? An ecological analysis of European incidence rates. Diabetologia 2001; 44: B9-B16.
123. Rytkonen M, Moltchanova E, Ranta J, Taskinen O, Tuomilehto J, Karvonen M. The incidence of type 1 diabetes among children in Finland-rural-urban difference. Health Place 2003; 9: 315-25.
124. Rytkonen M, Ranta J, Tuomilehto J, Karvonen M. Bayesian analysis of geographical variation in the incidence of Type 1 diabetes in Finland. Diabetologia 2001; 44: B37-44.
125. Casu A, Pascutto C, Bernardinelli L, Songini M. Type 1 diabetes among sardinian children is increasing: the Sardinian diabetes register for children aged 0-14 years (1989-1999). Diabetes Care 2004; 27: 1623-1629.
126. Virtanen SM, Kenward MG, Erkkola M, et al. Age at introduction of new foods and advanced beta cell autoimmunity in young children with HLA-conferred susceptibility to type 1 diabetes. Diabetologia 2006; 49: 1512-1521.
127. Lindholm P, Kortemaa H, Kokkola M, Haahtela K, Salkinoja-Salonen M, Valkonen JPT. Streptomyces spp. isolated from potato scab lesions under nordic conditions in Finland. Plant Dis 1997; 81: 1317-22.
128. Mori M. Establishing a stable potato production system in Japan and developing new varieties with specific end-use characteristics. Potato Breeding Laboratory, Department of Upland Agriculture. National Agricultural Research Center for Hokkaido Region 2004.
129. Miyajima K, Tanaka F, Takeuchi T, Kuninaga S. Streptomyces turgidiscabies sp. Int J Syst Bacteriol 1998; 48: 495-502.
130. Matsuura N, Fukuda K, Okuno A, et al. Descriptive epidemiology of IDDM in Hokkaido, Japan: the Childhood IDDM Hokkaido Registry Diabetes Care 1998; 21: 1632-1636.
131. Shi Y, Taylor S, Tan S, Sonenberg N. When translation meets metabolism. Endo Rev 2006; 24: 91-101.
132. Ozcan U, Yilmaz E, Ozcan L, et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of Type 2 Diabetes. Science 2006; 313: 1137-1140.